Trials / Conditions / Refractory Melanoma

Refractory Melanoma

12 registered clinical trials studyying Refractory Melanoma — 3 currently recruiting.

Status	Trial	Sponsor	Phase
Recruiting	DOC1021 Dendritic Cell Immunotherapy for Refractory Melanoma NCT07288112	Diakonos Oncology Corporation	Phase 1 / Phase 2
Recruiting	Phase 1 Dose Escalation and Expansion Study of PRAME T Cell Receptor (TCR) Engineered NK Cells in Participants NCT06660420	M.D. Anderson Cancer Center	Phase 1
Terminated	Polarized Dendritic Cell (aDC1) Based Treatment, Interferon Alpha-2, Rintatolimod, and Celecoxib for the Treat NCT04093323	Roswell Park Cancer Institute	Phase 2
Suspended	Rigosertib Plus Pembrolizumab in Treating Patients With Unresectable/Metastatic Melanoma Refractory to PD-1 In NCT05764395	Vanderbilt-Ingram Cancer Center	Phase 2
Completed	Pixatimod (PG545) Plus Nivolumab in PD-1 Relapsed/Refractory Metastatic Melanoma and NSCLC and With Nivolumab NCT05061017	Diwakar Davar	Phase 2
Recruiting	IACS-6274 With or Without Bevacizumab and Paclitaxel for the Treatment of Advanced Solid Tumors NCT05039801	M.D. Anderson Cancer Center	Phase 1
Active Not Recruiting	Tipifarnib for the Treatment of Advanced Solid Tumors, Lymphoma, or Histiocytic Disorders With HRAS Gene Alter NCT04284774	National Cancer Institute (NCI)	Phase 2
Active Not Recruiting	Bevacizumab and Atezolizumab With or Without Cobimetinib in Treating Patients With Untreated Melanoma Brain Me NCT03175432	M.D. Anderson Cancer Center	Phase 2
Active Not Recruiting	Testing the PD-1 Antibody, MK3475, Given With Ziv-aflibercept in Patients With Advanced Cancer NCT02298959	National Cancer Institute (NCI)	Phase 1
Completed	Nivolumab With or Without Ipilimumab in Treating Younger Patients With Recurrent or Refractory Solid Tumors or NCT02304458	National Cancer Institute (NCI)	Phase 1 / Phase 2
Completed	Study of CP-675,206 in Refractory Melanoma NCT00254579	AstraZeneca	Phase 2
No Longer Available	Compassionate Use of Vidutolimod NCT06063746	Regeneron Pharmaceuticals	—